- Home
- ASGN vs PVLA Comparison
ASGN vs PVLA Comparison
Compare ASGN & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASGN | PVLA |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASGN | PVLA |
|---|---|---|
| Price | $38.46 | $119.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $51.20 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 653.6K | 249.3K |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.60 | N/A |
| Revenue | ★ $3,980,400,000.00 | N/A |
| Revenue This Year | $3.26 | N/A |
| Revenue Next Year | $4.94 | $93,193.48 |
| P/E Ratio | $14.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $34.59 | $18.23 |
| 52 Week High | $62.42 | $151.18 |
Technical Indicators
Market Signals| Indicator | ASGN | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 51.12 |
| Support Level | $34.59 | $108.99 |
| Resistance Level | $40.16 | $147.47 |
| Average True Range (ATR) | 1.69 | 8.70 |
| MACD | 0.44 | -0.84 |
| Stochastic Oscillator | 71.36 | 43.28 |
Price Performance
Historical ComparisonAbout ASGN ASGN Incorporated
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.